A new era has opened in Malawi’s cancer response with the country’s hosting, in April, of a high-level delegation of medical and advocacy experts aiming to combat one of its deadliest diseases: esophageal cancer (EC).
The groundbreaking public health initiative brought together distinguished personalities, including Malawi’s Ambassador to the United States, Judge Esme Chombo; Emeritus Professor at the Mayo Clinic and Chairman of the AfrECC Foundation Board, Dr David Fleischer, and humanitarian and CEO of Encase Consulting Group, Ike Ogbuebile, who joined forces with global medical device leader Boston Scientific (market capitalization: $156.88 billion) led by Art Butcher, Executive Vice President for Boston Scientific; Ms Camille Chang Gilmore, Global CDO; Carl Budge, Head of Global Outreach, the African Esophageal Cancer Consortium (AfrECC), and Malawi’s Ministry of Health.
Malawi holds the highest reported global age-standardized rate for esophageal squamous cell carcinoma (ESCC) incidence and mortality. Esophageal cancer is the third most common cancer in the country, posing a serious public health challenge due to late diagnoses and scarce treatment options.
The initiative saw the delegation travel to high-risk areas such as Salima and Nkhoma, where they conducted community outreach sessions to raise awareness of early symptoms—difficulty swallowing, unexplained weight loss, and chronic heartburn—and emphasized the importance of early medical evaluation. They deployed mobile screening units to local clinics, enabling on-site preliminary endoscopic exams and providing life-saving diagnostic services directly to underserved populations.
Read Also: BridgeAFRIC signs Malawian gospel artist Rudo Chakwera
A centerpiece of the mission was the introduction of Boston Scientific’s Ultraflex™ Esophageal Stent. Under the expert guidance of Dr. Fleischer, more than 25 Malawian doctors and clinical officers received hands-on training in stent placement, a life-improving technology that restores swallowing function for patients with obstructive tumors, offering immediate relief and improved quality of life—even in late-stage cases.
The initiative’s long-term vision was emphasized during workshops at the Ministry of Health headquarters in Lilongwe, attended by Ambassador Chombo, who led the U.S. delegation. The program promotes sustainable impact by combining advanced medical technology with local capacity-building, ongoing education, and peer-to-peer mentorship.
Encase Consulting Group’s CEO Ike Ogbuebile played a pivotal role in the mission, leading high-level stakeholder engagement, securing key partnerships, and advocating for resource allocation within the Malawian health system. His leadership and commitment to healthcare equity across Africa amplified community voices and drew international attention to the urgent need for comprehensive cancer control strategies on the continent.
The mission also included high-level talks with Malawi’s President Lazarus Chakwera, as well as engagements with the U.S. Embassy, the World Health Organization’s representative to Malawi, and the Chancellor of the Malawi University of Science and Technology. There was also an outreach in high-incidence villages, reinforcing the initiative’s grassroots approach.
Experts say the initiative was more than a single intervention as it marked the beginning of a new era in Malawi’s cancer response. They add that by uniting innovation, training, and community empowerment, Malawi is charting a bold path forward—one that could serve as a model for other nations facing similar public health challenges.
In his remarks, Ogbuebile reminded the delegation of the essence of the visit and the commitment to stand by Malawi and Africa. “Africa needs us, and we can’t forget the faces, the warmth and the challenges of the people we met during this experience,” he said.
